JS015 combination therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called JS015 combined with standard treatments for several advanced solid tumors. It may be an option if you have esophageal, stomach, colorectal, or pancreatic cancer that has spread and you've already had standard first-line therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of advanced cancer: esophageal, stomach (not HER2-positive), colorectal, or pancreatic cancer.
- For most types, you need to have already tried standard first-line treatment and it stopped working. (Some stomach or pancreatic cancer patients may not need prior treatment.)
- You must be able to take care of yourself and be up and about (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You cannot have active brain metastases, fluid buildup needing drainage, a history of serious lung inflammation, or a recent hole or leak in your digestive tract.
- Your heart, lungs, liver, and kidneys must be working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced solid tumors that are no longer responding to standard treatments. It focuses on patients whose tumors have high levels of a protein called CCNE1, particularly for certain ovarian, fallopian tube, peritoneal, and uterine cancers.
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.